5 completed, 2 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Lymphoma, Primary Cutaneous Anaplastic Large Cell: new trials by email Literature Review of Lymphoma, Primary Cutaneous Anaplastic Large Cell trials Research Report on Lymphoma, Primary Cutaneous Anaplastic Large Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Completed | John Reneau | 26 | 2018-03-16 | 2026-08-13 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Cholecalciferol, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | Not applicable | Active not recruiting | Mayo Clinic | 565 | 2013-03-06 | 2026-06-16 |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Brentuximab Vedotin, Methotrexate, Bexarotene - Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 131 | 2012-06-11 | 2021-01-05 |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) SGN-35 - CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 79 | 2011-06-01 | 2026-07-16 |
| Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Pralatrexate Injection, Bexarotene Capsules, Vitamin B12 - Cutaneous T-cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | Acrotech Biopharma Inc. | 34 | 2010-03-01 | 2019-12-18 |
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma MDX-060 - Lymphoma, Large-Cell | Phase 2 | Withdrawn | Bristol-Myers Squibb | 45 | 2006-02-01 | 2010-04-26 |
| Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma SGN-30 - Large Cell Lymphoma | Phase 2 | Completed | Seagen Inc. | 40 | 2004-09-01 | 2014-12-18 |
Mycosis Fungoides (6) · Lymphoma, T-Cell, Cutaneous (5) · Lymphoma, Large-Cell, Anaplastic (4) · Lymphoma, T-Cell (4) · Enteropathy-Associated T-Cell Lymphoma (3) · Immunoblastic Lymphadenopathy (3) · Lymphoma (3) · Lymphoma, Extranodal NK-T-Cell (3) · Lymphomatoid Papulosis (3) · Sezary Syndrome (3) · Subcutaneous panniculitis-like T-cell lymphoma (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma, Non-Hodgkin (9) · Lymphoma (7) · Lymphoma, T-Cell (6) · Lymphoma, T-Cell, Cutaneous (5) · Disease Attributes (3) · Hematologic Diseases (3) · Histiocytic Disorders, Malignant (3) · Leukemia (3)
Brentuximab Vedotin (5) · Bexarotene (2) · 10-propargyl-10-deazaaminopterin (1) · Cholecalciferol (1) · Folic Acid (1) · Lenalidomide (1) · Lisaftoclax (1) · Methotrexate (1) · Salvia hispanica seed extract (1) · Vitamin B 12 (1) · iratumumab (1)
Mayo Clinic (2) · Acrotech Biopharma Inc. (1) · Bristol-Myers Squibb (1) · John Reneau (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Millennium Pharmaceuticals, Inc. (1) · Peking University First Hospital (1) · Seagen Inc. (1)
United States (9) · France (2) · Italy (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Germany (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Auris O Huen, MD (1) · John Reneau, MD (1) · Pankaj Sharma, MD (1) · Steven Horwitz, MD (1) · Thomas E. Witzig, MD (1) · Thomas Witzig (1)
PMID 19789316, PMID 28600132, PMID 28980004, PMID 32502876, PMID 32632956, PMID 33794441, PMID 34507350
P30CA015083 (1), P50CA097274 (1)